Results from the lab and animal trials have shown that GlucoSet sensors have high accuracy, in particular in the low blood glucose ranges, which is important to enable tight glucose control.

These outstanding correlations [between the GlucoSet sensor and blood gas measurements] appeared to be even tighter in the severely hypoglycemic range—an important feature of any glucose-measuring device, especially in the context of intensive insulin therapy.
— Inzucchi & Kosiborod, in the editorial of Anesthesiology (2011)




The GlucoSet sensor is a biosensor with a hydrogel matrix incorporated with 3-phenylboronic acid. The gel contracts at rising glucose concentrations as a consequence of glucose-induced cross-binding of phenylboronic molecules. The hydrogel is fabricated at the tip of an optical fiber, and the whole sensor is covered with a semipermeable coating. The diameter of the gel is measured by an interferometric technique (illustration on the right). Changes in glucose concentration cause the volume of the gel to change, causing its diameter to change accordingly. 


The GlucoSet technology was designed from the start to be manufactured in small volumes in the lab for R&D just as well as on an industrial scale for use in clinics. GlucoSet holds patents for the manufacturing process.


GlucoSet holds several patents for different aspects of the sensor technology platform in key markets. The IP portfolio is in continual development.


  • Skjaervold, Nils K., et al. "Continuous Measurement of Blood Glucose." Anesthesiology 114.1 (2011): 1.
  • Inzucchi, Silvio E., and Mikhail Kosiborod. "Continuous glucose monitoring during critical care." Anesthesiology 114.1 (2011): 18-19.